# K102385: Norfolk Medical Norport Family of Ports

- Pathway: 510(k) (Traditional)
- Applicant: Norfolk Medical Products, Inc.
- Decided: Jan 14, 2011 after 144 days
- Product code: LJT (Port & Catheter, Implanted, Subcutaneous, Intravascular)
- Device class: 2
- Regulation: 21 CFR 880.5965
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 10 generations back to K001901 (2000). 44 ancestors in all.
3 later devices descend from it; 1 cites it directly.
0 of 48 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K091099: C-Port - HP Power Injectable Port, Phs Medical GmbH (2009) Summary page 9.
- K060812: Powerport (TM)Implanted Titanium Port W/8 FR. Chronoflex Catheter-Multiple, C.R. Bard, Inc. (2006) Summary page 9.
- K081472: Smartport CT Vortex; LP Titanium, Single Plastic, Single Titanium, Triumph Low Profile Titanium Ports, AngioDynamics, Inc. (2008) Summary page 2.
- K830000: Vascular-Access-Port, Norfolk Medical Products, Inc. (1983) Summary page 9.
- K871192: Subcutaneously Implanted Drug Delivery Depot, Norfolk Medical Products, Inc. (1987) Summary page 2.
- K871209: Norfolk Medical Norport, Norfolk Medical Products, Inc. (1987) Summary page 2.
- K863723: Norfolk Norport/Subcutan. Implanted Drug Depot, Norfolk Medical Products, Inc. (1986) Summary page 2.
- K840788: Vascular Access Port Changes in Mater, Norfolk Medical Products, Inc. (1984) Summary page 2.

## Most influential descendants
- K111101: Norport CT-PC, Lucent Non-Coring Needel Infusion Set (2011), 2 descendants of its own
- K112713: Norfolk Medical-Sportport-Family of Ports (2011), 1 descendant of its own
- K192291: TidalPort-AP Implantable Apheresis Vascular Access Port (2020), 0 descendants of its own

## Indications for use
The NorPort Family of Implanted Vascular Access Devices is indicated for use when the patient requires repeated access to the vascular system for injections, infusion dmugs, administration of blood or blood products, and/or withdrawal of blood as part of the therapy regimen.

Source page: https://510kreport.com/device/K102385
Methodology: https://510kreport.com/methodology